AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 302 min read$GLUE

Janku Filip sold $138K of GLUE

Janku Filip (Chief Medical Officer) sold 6,000 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $22.95 ($0.14M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Janku Filip
Published Jun 30, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GLUE
Neutral
high confidence
Mentioned
$GLUE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUENeutralLow
01

Why it matters

The newest disclosed fact is the June 29 open-market sale of 6,000 shares by the CMO at $22.95, filed June 30, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and small dollar amount relative to typical biotech flows imply limited trading edge.

03

What to watch

The filing doesn’t disclose reasons for sale; also, the post-sale holdings (59,992 shares) suggest the insider remains materially invested.

Relevance 3/10Novelty 3/10Timing: filed June 30 after the June 29 sale

Background

This is an SEC Form 4 insider transaction for Monte Rosa Therapeutics, Inc. (GLUE).

Company-level read

Ticker impact

$GLUENeutralHigh confidence
Context

Monte Rosa Therapeutics’ CMO Janku Filip sold 6,000 shares at $22.95 under a pre-arranged 10b5-1 plan, totaling $137.7K.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and small.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.

Market effects

Sector

No sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can be purely mechanical (tax/portfolio rebalancing) and may not reflect bearish expectations.

Key entities

  • equity issuer
    GLUE

    Monte Rosa Therapeutics, Inc.; subject of the insider sale disclosure.

  • insider
    Janku Filip

    Chief Medical Officer who executed the 10b5-1 sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GLUE insider trading history →

Related articles

OCT 11
$GLUEMed

Monte Rosa Therapeutics assumed with a Buy at UBS

UBS initiated coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and $19 price target, citing the potential of its drug MRT-8102 for chronic inflammatory diseases. The firm highlights the drug's differentiated profile and the company's atherosclerotic cardiovascular disease opportunity.

tipranks.com1 min
OCT 5
$GLUEMedAI 8/10

H.C. Wainwright reiterates Monte Rosa stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $25.00 price target on Monte Rosa Therapeutics (GLUE) after positive clinical trial results for MRT-8102. The stock is currently trading at $10.50, down 10% over the past week. Jefferies also raised its price target to $40, maintaining a Buy rating. The company is conducting a phase 2 study for metastatic prostate cancer and expects further clinical data catalysts in 2026 and 2027.

investing.com2 min
OCT 3
$GLUEMedAI 8/10

Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win

Monte Rosa Therapeutics reported positive Phase 1 results for MRT-8102, showing significant biomarker reductions and no serious adverse events. The data supports its planned Phase 2b study in coronary artery disease. The company forecasts revenue of $88.1M and earnings of $15.2M by 2029, with current losses of $161.1M and revenue of $28.7M.

simplywall.st2 min
OCT 1
$GLUEMedAI 8/10

Monte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1

Monte Rosa Therapeutics (GLUE) reported Phase 1 results showing MRT-8102 achieved 80%-90% NEK7 degradation, reducing biomarkers linked to cardiovascular disease. The treatment was well-tolerated with no serious adverse events. GLUE plans Phase 2 trials in 2026-2027 for coronary artery disease, gout, and hidradenitis suppurativa. GLUE stock is currently down 5.74% at $11.24.

rttnews.com2 min